Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates

Kyle LaHucik

Senior Reporter

Sudo Biosciences has raised a $116 million Series B from well-known investors and Sanofi’s VC arm, the transatlantic biotech told Endpoints News, as it looks …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Ex­clu­sive: Su­do Bio­sciences se­cures $116M to start tri­als of its oral and top­i­cal TYK2 can­di­dates

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates